An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis

Inclusion Criteria:

• At least 18 years of age, at the time of signing the informed consent.

• Diagnosed with Generalized Myasthenia Gravis (gMG) with confirmed documentation andsupported by a physical exam and confirmed seropositivity for anti-acetylcholinereceptor antibodies (AChR-Abs).

• Meets the clinical criteria as defined by the Myasthenia Gravis Foundation ofAmerica (MGFA) class II, III, or IV

Exclusion Criteria:

• Any other condition that, in the opinion of the investigator, would interfere withan accurate assessment of the clinical symptoms of gMG and/or put the participant atundue risk

• A thymectomy within 3 months of screening

• Use of the following prior or concomitant therapies:

1. intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) within 14 days of day 1

2. Rituximab within 6 months of day 1

3. Eculizumab within 1 month of day 1

4. Other monoclonal antibodies (eg, adalimumab, tocilizumab, ixekizumab)